TELA Bio, Inc.

$0.93+8.66%(+$0.07)
TickerSpark Score
75/100
Solid
100
Valuation
60
Profitability
95
Growth
68
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TELA research report →

52-Week Range26% of range
Low $0.50
Current $0.93
High $2.20

Companywww.telabio.com

TELA Bio, Inc. , a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

CEO
Antony Koblish
IPO
2019
Employees
209
HQ
Malvern, PA, US

Price Chart

-24.82% · this period
$2.14$1.35$0.56May 20Nov 18May 20

Valuation

Market Cap
$41.83M
P/E
-1.34
P/S
0.52
P/B
-10.29
EV/EBITDA
-1.78
Div Yield
0.00%

Profitability

Gross Margin
67.25%
Op Margin
-41.84%
Net Margin
-49.30%
ROE
-1344.47%
ROIC
-64.94%

Growth & Income

Revenue
$80.28M · 15.84%
Net Income
$-38,831,000 · -2.62%
EPS
$-0.83 · 37.59%
Op Income
$-33,755,000
FCF YoY
32.68%

Performance & Tape

52W High
$2.20
52W Low
$0.50
50D MA
$0.77
200D MA
$1.14
Beta
1.30
Avg Volume
183.72K

Get TickerSpark's AI analysis on TELA

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 1, 26Langstein Howard N.other0
Mar 1, 26Langstein Howard N.other72,750
Feb 20, 26KOBLISH ANTONYother176,000
Feb 21, 26KOBLISH ANTONYother12,494
Feb 23, 26KOBLISH ANTONYother11,631
Feb 24, 26KOBLISH ANTONYother3,900
Feb 20, 26KOBLISH ANTONYother261,000
Feb 20, 26Firestone Gregory A.other37,000
Feb 21, 26Firestone Gregory A.other4,189
Feb 23, 26Firestone Gregory A.other1,352

Our TELA Coverage

We haven't published any research on TELA yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate TELA Report →

Similar Companies